Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent†
Abstract
Herein, we describe new
* Corresponding authors
a
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt
E-mail:
ashraf.abadi@guc.edu.eg
Fax: +20 2-27581041
b Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany
c Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus C2.3, D-66123 Saarbrücken, Germany
d Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Egypt
e Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Saudi Arabia
f Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Suite 3029, Mobile, AL 36604, USA
Herein, we describe new
M. M. Hamed, D. A. Abou El Ella, A. B. Keeton, G. A. Piazza, M. Engel, R. W. Hartmann and A. H. Abadi, Med. Chem. Commun., 2013, 4, 1202 DOI: 10.1039/C3MD00118K
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content